Kazia Therapeutics (KZIA) AI Stock Analysis

• Market Cap: $84.91M
• Dividend Yield: N/A
• Average Volume (3M): 209.48K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: -98.25%
• EPS Growth: 63.05%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 11,335,992
• 10 Day Avg. Volume: 60,839
• 30 Day Avg. Volume: 209,481
• PEG Ratio: <0.01
• Price to Book (P/B): -1.26
• Price to Sales (P/S): 248.45
• P/FCF Ratio: -0.79
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: 319.01
• Enterprise Value/Gross Profit: 319.01
• Enterprise Value/Ebitda: -1.01
• 1Y Price Target: $19.00
• Price Target Upside: 195.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: $7.50 ▲(16.46% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is held down primarily by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn with negative equity). Technicals are a notable offset with strong momentum above major moving averages, but overbought signals add near-term risk; valuation remains challenged due to negative earnings and no dividend support.

Positive Factors

Clinical pipeline expansion (paxalisib)

Positive early efficacy in a paxalisib + pembrolizumab chemo combo in metastatic TNBC suggests the asset can address indications beyond brain cancers. If durable in expanded cohorts, this structurally broadens addressable markets, strengthens partner/licensing leverage and raises long-term commercial potential.

Low absolute debt burden

Very low reported debt reduces near-term creditor and interest-rate pressure, preserving operational flexibility. For a cash-burning biotech, minimal leverage lowers default risk and keeps balance-sheet capacity available for strategic financing or partnerships when raising funds for clinical programs.

NASDAQ listing compliance regained

Restoring Nasdaq compliance removes immediate delisting risk and preserves access to US capital markets. This is a structural positive because it maintains the company’s ability to raise public equity, use its ADSs in collaborations, and avoid disruptive market/legal consequences that would impede long-term funding and commercialization plans.

Negative Factors

Persistent cash burn and negative FCF

Consistent multi-year negative operating and free cash flow indicates reliance on external financing to sustain trials. This structurally increases dilution risk, can limit program runway if markets tighten, and forces management to prioritize fundraising over long-term R&D sequencing and commercialization investments.

Negative equity and shrinking asset base

Negative shareholder equity and a materially shrinking asset base reflect accumulated losses and capital erosion. Structurally this weakens borrowing capacity, may complicate partnering or licensing negotiations, and reduces the financial cushion available to absorb clinical setbacks or funding delays.

Extremely small, volatile revenue and large losses

A tiny, inconsistent revenue base combined with large operating losses means the business is far from self-sustaining. This structural mismatch prolongs the path to profitability, increases dependency on capital markets or partners, and raises execution risk for advancing late-stage or multiple indication programs.

Kazia Therapeutics Business Overview & Revenue Model

Company Description

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

How the Company Makes Money

null

Kazia Therapeutics Financial Statement Overview

Summary

Financials are very weak: revenue is extremely small and volatile (down to ~$42K in 2025 from ~$2.3M in 2024), losses remain large (net loss ~$20.7M in 2025), and operating/free cash flow are consistently negative (FCF about -$13.3M in 2025). Low absolute debt helps, but negative equity and a shrinking asset base materially raise funding and execution risk.

Income Statement

The revenue base is extremely small and volatile, with annual revenue dropping to ~$42K in 2025 from ~$2.3M in 2024 (sharp contraction after a prior spike). Profitability remains deeply negative: EBIT and net income are consistently large losses (e.g., net loss of ~$20.7M in 2025 and ~$26.8M in 2024), indicating ongoing high operating spend relative to revenue. A key positive is that gross profit equals revenue in the periods shown, but the business is still far from covering operating costs.

Balance Sheet

Leverage is low in absolute terms (total debt ~ $0.4M in 2025, down from ~$0.6M in 2024), which reduces near-term balance sheet risk from creditors. However, equity has turned negative (stockholders’ equity of about -$8.3M in 2025 and -$10.0M in 2024), which is a meaningful weakness and reflects accumulated losses and capital erosion. Total assets also fell materially (to ~$6.1M in 2025 from ~$21.6M in 2024), pointing to a shrinking balance sheet and potentially reduced financial flexibility.

Cash Flow

Cash generation remains a clear weakness: operating cash flow and free cash flow are consistently negative across all years shown, including about -$13.3M in 2025 and -$9.6M in 2024, implying continued cash burn to fund operations. Free cash flow improved versus 2024 (as indicated by positive free cash flow growth in 2025), but the company is still reliant on external funding to sustain operations. The pattern over multiple years suggests limited self-funding capacity until revenue scales materially or costs are reduced.

Breakdown	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	42.00K	2.31M	555.00	10.00K	15.18M
Gross Profit	42.00K	2.31M	555.00	10.00K	15.18M
EBITDA	-13.28M	-26.59M	-22.28M	-23.52M	-5.11M
Net Income	-20.70M	-26.78M	-20.47M	-25.01M	-8.42M
Balance Sheet
Total Assets	6.06M	21.59M	28.08M	35.89M	58.09M
Cash, Cash Equivalents and Short-Term Investments	4.34M	1.66M	5.24M	7.36M	27.59M
Total Debt	396.00K	634.00K	1.80M	1.84M	0.00
Total Liabilities	14.36M	31.60M	16.03M	17.61M	20.24M
Stockholders Equity	-8.30M	-10.02M	12.05M	18.27M	37.85M
Cash Flow
Free Cash Flow	-13.28M	-9.58M	-15.16M	-22.76M	-9.11M
Operating Cash Flow	-13.28M	-9.58M	-15.16M	-22.76M	-9.11M
Investing Cash Flow	0.00	0.00	0.00	-2.37M	0.00
Financing Cash Flow	15.98M	5.99M	12.97M	3.73M	28.11M

Kazia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.44
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZIA, the sentiment is Negative. The current price of 6.44 is below the 20-day moving average (MA) of 7.53, below the 50-day MA of 6.85, and below the 200-day MA of 7.81, indicating a neutral trend. The MACD of 0.41 indicates Positive momentum. The RSI at 49.42 is Neutral, neither overbought nor oversold. The STOCH value of 17.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KZIA.

Kazia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHIO	53 Neutral	$13.59M	-1.29	-107.58%	―	―	83.95%
MRKR	53 Neutral	$22.18M	―	-92.35%	―	-12.99%	-13.67%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
KZIA	49 Neutral	$84.91M	-0.50	337.03%	―	-98.25%	63.05%
RNAZ	49 Neutral	$8.97M	-0.46	-684.86%	―	―	96.75%
XTLB	39 Underperform	$6.32M	-5.36	―	―	―	65.45%

Kazia Therapeutics Corporate Events

Kazia Therapeutics Posts Early Efficacy Signals for Paxalisib Combo in Metastatic Triple-Negative Breast Cancer

On January 27, 2026, Kazia Therapeutics reported encouraging early clinical signals from an ongoing Phase 1b trial of paxalisib in combination with pembrolizumab and chemotherapy in late-stage metastatic triple-negative breast cancer, initiated in June 2025, with two of two evaluable trial patients achieving partial responses and a separate expanded-access patient demonstrating a confirmed complete metabolic response. The company said responses occurred in heavily burdened patients with visceral and multi-organ disease, treatment duration has reached a median of roughly 6.1 months with all patients remaining on therapy, and safety at the 30 mg daily dose appears manageable with mostly mild to moderate adverse events, findings that, if confirmed in the planned expansion of study sites through 2026 and additional breast cancer cohorts, could enhance paxalisib’s profile beyond brain cancers and potentially strengthen Kazia’s position in the highly competitive immuno-oncology and breast cancer treatment landscape.

The most recent analyst rating on (KZIA) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.

Kazia Therapeutics Retains Nasdaq Listing After Regaining Compliance

On December 18, 2025, Kazia Therapeutics Limited regained compliance with Nasdaq’s continued listing standards by meeting the alternative minimum stockholders’ equity requirement of $2.5 million under Listing Rule 5550(b)(1), after previously being notified on November 12, 2025 that it had failed to satisfy the $35 million market value of listed securities threshold by November 10, 2025. As a result, a Nasdaq hearing that had been scheduled for January 8, 2026 to address potential suspension or delisting was cancelled, and Nasdaq confirmed that Kazia’s ADSs will continue trading on the Nasdaq Capital Market, removing an immediate overhang of listing risk for the company and its investors.

The most recent analyst rating on (KZIA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.